drugset
drugset / Trial / NCT00730613

Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma

NCT00730613 ↗

Phase 1 Completed 3 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Cellular adoptive immunotherapy may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This clinical trial is studying the side effects of cellular adoptive immunotherapy using genetically modified T-lymphocytes and to see how well it works in treating patients with recurrent or refractory high-grade malignant glioma.

Timeline

Start
2002-03-25
Primary completion
2011-08-01
Completion
2011-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject therapeutic autologous lymphocytes Cell therapy 1e+08 cells —

Indications

central nervous system neoplasm